Get started
Author

Viola Poeschel

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
2008 · Michael Pfreundschuh, Joerg Schubert, et al. · The Lancet Oncology · 1,130
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
2011 · Michael Pfreundschuh, Evelyn Kuhnt, et al. · The Lancet Oncology · 792
International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI
2020 · Amy S. Ruppert, Jesse G. Dixon, et al. · Blood · 366
PDF
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial
2019 · Viola Poeschel, Gerhard Held, et al. · The Lancet · 254
PDF
The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL
2012 · Carsten Müller, Niels Murawski, et al. · Blood · 243
PDF
Suboptimal dosing of rituximab in male and female patients with DLBCL
2013 · Michael Pfreundschuh, Carsten Müller, et al. · Blood · 142
Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group
2014 · Michael Pfreundschuh, Viola Poeschel, et al. · Journal of Clinical Oncology · 89
Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL
2014 · N. Murawski, M. Pfreundschuh, et al. · Annals of Oncology · 70
A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL
2020 · Norbert Schmitz, Lorenz H Truemper, et al. · Blood · 69
PDF
Association of NADPH Oxidase Polymorphisms with Anthracycline-Induced Cardiotoxicity in the RICOVER-60 Trial of Patients with Aggressive CD20 + B-Cell Lymphoma
2015 · Annegret Reichwagen, Marita Ziepert, et al. · Pharmacogenomics · 58
Six, Not Eight Cycles of Bi-Weekly CHOP with Rituximab (R-CHOP-14) Is the Preferred Treatment for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
2005 · Michael Pfreundschuh, Marita Kloess, et al. · Blood · 56
Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL/GLA.
2018 · Michael Pfreundschuh, Niels Murawski, et al. · Journal of Clinical Oncology · 50
Six versus eight cycles of biweekly CHOP-14 with or without R in elderly patients (pts) with aggressive CD20+ B-cell lymphomas: Seven-year FU of the RICOVER-60 trial of the DSHNHL.
2011 · M. Pfreundschuh, M. Ziepert, et al. · Journal of Clinical Oncology · 47
FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials
2021 · Dominic Kaddu-Mulindwa, Bettina Altmann, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 40
PDF
Hyper-N-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma
2018 · Lorenz Thurner, Klaus-Dieter Preuss, et al. · Blood · 37
PDF
Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient Outcomes
2023 · Daniel Noerenberg, Franziska Briest, et al. · Journal of Clinical Oncology · 36
A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL
2019 · the Emed Demonstrator Project, Annette M. Staiger, et al. · Leukemia · 36
Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL.
2017 · Michael Pfreundschuh, Konstantinos Christofyllakis, et al. · Journal of Clinical Oncology · 36
Six vs. Eight Cycles of Bi-Weekly CHOP-14 with or without Rituximab for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Completed RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
2006 · Michael Pfreundschuh, Marita Kloess, et al. · Blood · 30
SPARC-positive macrophages are the superior prognostic factor in the microenvironment of diffuse large B-cell lymphoma and independent of MYC rearrangement and double-/triple-hit status
2021 · G.A. Croci, R.K.H. Au-Yeung, et al. · Annals of Oncology · 29
Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL) after dose-dense rituximab: Results of the DENSE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
2008 · M. Pfreundschuh, S. Zeynalova, et al. · Journal of Clinical Oncology · 29
Relapsed/Refractory International Prognostic Index (R/ R‐IPI ): An international prognostic calculator for relapsed/refractory diffuse large B‐cell lymphoma
2021 · Matthew J. Maurer, Lasse H. Jakobsen, et al. · American Journal of Hematology · 26
PDF
Landscape of 4D Cell Interaction in Hodgkin and Non-Hodgkin Lymphomas
2021 · Sylvia Hartmann, Sonja Scharf, et al. · Cancers · 20
PDF
Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial
2023 · Gerhard Held, Lorenz Thurner, et al. · HemaSphere · 19
B-cell receptor reactivity against Rothia mucilaginosa in nodular lymphocyte-predominant Hodgkin lymphoma
2023 · Lorenz Thurner, Natalie Fadle, et al. · Haematologica · 18
PDF
Works count: 108
Citation count: 4,017
H-index: 22
I10-index: 36
Year
Topic
Type